A Single Blind, Randomized, Placebo Controlled, Crossover Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Oral Escalating Doses of GSK586529 in Healthy Volunteers

Trial Profile

A Single Blind, Randomized, Placebo Controlled, Crossover Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Oral Escalating Doses of GSK586529 in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs GSK 586529 (Primary)
  • Indications Anxiety disorders; Major depressive disorder
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 22 Jun 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Jun 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top